|  |  |  |
| --- | --- | --- |
| **PROFILE** | | |
| **1** | **NAME** | AHMED MAHMOUD ALAFEEFY |
| **2** | **ACADEMIC POSITION** | Professor |
| **3** | **STATUS OF APPOINTMENT** | CONTRACT |
| **4** | **CITIZENSHIP** | EGYPTIAN |
| **5** | **EDUCATION** | PhD (2005), University – HELWAN UNIVERSITY;  Bachelor of PHARMACY (Hons) (1983), University of ZAGAZIG2003. |
| **6** | **WORKING EXPERIENCE** | * DEMONSTRATOR, FACULTY OF PHARMACY, ALAZHAR UNIVERSITY, CAIRO, EGYPT, 2 APRIL 1985 - 11 OCTOBER 1992. * LECTURER, FACULTY OF PHARMACY, KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA 12 OCTOBER 1992 - 25 SEPTEMBER 2008. * ASSISTANT PROFESSOR, FACULTY OF PHARMACY, KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA, 26 SEPTEMBER 2008 - 25 JUNE 2010. * ASSOCIATE PROFESSOR, FACULTY OF PHARMACY, ALKHARJ UNIVERSITY, ALKHARJ, SAUDI ARABIA, 26 JUNE 2010 -26 AUGUST 2015. * ASSISTANT PROFESSOR, KULLIYYAH OF SCIENCE, IIUM UNIVERSITY, KUANTAN, MALAYSIA, 01 APRIL 2016 -10 JULY 2017. * SCIENTIFIC OFFICE MANAGER, FAMILY PHARMACIA, RIYADH, SAUDI ARABIA, 10 JULY 2017 – 30 MARCH 2019. * PROFESSOR, FACULTY OF PHARMACY, UITM, PUNCAK ALAM, SELANGOR, MALAYSIA |
| **7** | **CURRENT ACADEMIC RESPONSIBILITIES** | * PHC414, PHC464, PHC511, PHC631 |
| **8** | **RESEARCH INTERESTS/ PROJECTS** | * DRUG DISCOVERY (ANTITUMOR AGENTS) * MODERN TECHNIQUES OF DRUG DISCOVERY……… * DESIGN OF CAIX AND CAXII INHIBITORS |
| **9** | **PUBLICATIONS** | * Symmetric molecules with 1,4-triazole moieties as potent inhibitors of tumour-associated lactate dehydrogenase-A. 2- Altamimi AS, Alafeefy AM, Balode A, Vozny I, Pustenko A, El Shikh ME, Alasmary FAS, Abdel-Gawad SA, Žalubovskis R.J Enzyme Inhib Med Chem. 2018 Dec;33(1):147-150. doi: 10.1080/14756366.2017.1404593. * El-Sayed NNE, Almaneai NM, Ben Bacha A, Al-Obeed O, Ahmad R, Abdulla M, Alafeefy AM. Synthesis and evaluation of anticancer, antiphospholipases, antiproteases, and antimetabolic syndrome activities of some 3Hquinazolin-4-one derivatives. J Enzyme Inhib Med Chem. 2019;34(1):672-683. * Alasmary FAS, Awaad AS, Alafeefy AM, El-Meligy RM, Alqasoumi SI. Novel quinazoline and acetamide derivatives as safe anti-ulcerogenic agent and anti-ulcerative colitis activity. Saudi Pharm J. 2018;26(1):138-143. * Altamimi AS, Alafeefy AM, Balode A, Vozny I, Pustenko A, El Shikh ME, Alasmary FAS, Abdel-Gawad SA, Žalubovskis R. Symmetric molecules with 1,4-triazole moieties as potent inhibitors of tumour-associated lactate dehydrogenase-A. J Enzyme Inhib Med Chem. 2018;33(1):147-150. * Awaad AS, Alafeefy AM, Alasmary FAS, El-Meligy RM, Alqasoumi SI. Anti-ulcerogenic and anti-ulcerative colitis (UC) activities of seven amines derivatives. Saudi Pharm J. 2017;25(8):1125-1129. * Awaad AS, Alafeefy AM, Alasmary FAS, El-Meligy RM, Zain ME, Alqasoumi SI. Novel essential amino acid- sulfanilamide hybrid as safe anti-ulcerogenic agent with antihelicobacter pylori activity. Saudi Pharm J. 2017;25(7):967- 971. * Alasmary FAS, Alnahdi FS, Ben Bacha A, El-Araby AM, Moubayed N, Alafeefy AM, El-Araby ME. New quinoxalinone inhibitors targeting secreted phospholipase A2 and α-glucosidase. J Enzyme Inhib Med Chem. 2017;32(1):1143-1151. * Bozdag M, Alafeefy AM, Altamimi AM, Vullo D. Carta F, Supuran CT. Coumarins and other fused bicyclic heterocycles with selective tumor-associated carbonic anhydrase isoforms inhibitory activity. Bioorg Med Chem. 2017; 25(2):677-683. * Bozdag M, Alafeefy AM, Altamimi AM, Carta F, Supuran CT, Vullo D. Synthesis of new 3-(2-mercapto-4- oxo-4H-quinazolin-3-yl)-benzenesulfonamides with strong inhibition properties against the tumor associated carbonic anhydrases IX and XII. Bioorg Med Chem. 2017;25(10): 2782-2788. * Alafeefy AM, Carta F, Ceruso M, Al-Tamimi AM, AlKahtani AA, Supuran CT. Development of 3-(4- aminosulphonyl)-phenyl-2-mercapto-3H-quinazolin-4-ones as inhibitors of carbonic anhydrase isoforms involved in tumorigenesis and glaucoma. Bioorg Med Chem. 2016;24(6):1402-7. * - Alafeefy AM, Ahmad R, Abdulla M, Eldehna WM, AlTamimi AM, Abdel-Aziz HA, Al-Obaid O, Carta F, Al- Kahtani AA, Supuran CT. Development of certain new 2- substituted-quinazolin-4-yl-aminobenzenesulfonamide as potential antitumor agents. Eur J Med Chem. 2016;109:247- 53. * Alafeefy AM, Ashour AE, Prasad O, Sinha L, Pathak S, Alasmari FA, Rishi AK, Abdel-Aziz HA. Development of certain novel N-(2-(2-(2-oxoindolin-3- ylidene)hydrazinecarbonyl)phenyl)-benzamides and 3-(2- oxoindolin-3-ylideneamino)-2-substituted quinazolin-4(3H)- ones as CFM-1 analogs: design, synthesis, QSAR analysis and anticancer activity. Eur J Med Chem. 2015;92:191-201. * Alafeefy AM, Bakht MA, Ganaie MA, Ansarie MN, ElSayed NN, Awaad AS. Synthesis, analgesic, antiinflammatory and anti-ulcerogenic activities of certain novel Schiff's bases as fenamate isosteres. Bioorg Med Chem Lett. 2015;25(2):179-83. * Alafeefy AM, Ceruso M, Al-Tamimi AM, Del Prete S, Supuran CT, Capasso C. Inhibition studies of quinazolinesulfonamide derivatives against the γ-CA (PgiCA) from the pathogenic bacterium, Porphyromonas gingivalis. J Enzyme Inhib Med Chem. 2015;30(4):592-6. * - Alafeefy AM, Ceruso M, Al-Jaber NA, Parkkila S, Vermelho AB, Supuran CT. A new class of quinazolinesulfonamides acting as efficient inhibitors against the αcarbonic anhydrase from Trypanosoma cruzi. J Enzyme Inhib Med Chem. 2015;30(4):581-5. * - Alafeefy AM, Abdel-Aziz HA, Carta F, Supuran CT, Pathak SK, Prasad O, Sinha L. Exploring QSARs of some benzenesulfonamides incorporating cyanoacrylamide moieties as a carbonic anhydrase inhibitors (specifically against tumor-associated isoforms IX and XII). J Enzyme Inhib Med Chem. 2015;30(4):519-23. * Alafeefy AM, Awaad AS, Abdel-Aziz HA, El-Meligy RM, Zain ME, Al-Outhman MR, Bacha AB. Synthesis and biological evaluation of certain 3-substituted benzylideneamino-2-(4-nitrophenyl)quinazolin-4(3H)-one derivatives. J Enzyme Inhib Med Chem. 2015;30(2):270-6. * Alafeefy AM. Design, synthesis, and antitumor screening of certain novel tetrahydroquinoline sulfonamides. J Enzyme Inhib Med Chem. 2015;30(2):189-94.     Unpublished paper: Synthesis, Molecular Modeling and Biological Evaluation of Novel Quinoxaline Derivatives as Potential Treatment of Type II Diabetes |
| **10** | **RESEARCH GRANTS** |  |
| **11** | **AWARDS** | Gold Medal for the Best Researcher in The 4th Annual Meeting, Ministry of High Education, Saudi Arabia, 2015 |
| **12** | **INVOLVEMENT IN PROFESSIONAL ORGANISATIONS** | Active Member, American Association for Cancer Research (AACR). • Bentham Science Publishers 2015 – 2020. • The American Chemical Society (ACS) 1995 – 2015. • The Egyptian Syndicate of Pharmacists (ESP) 1984 – present. • The Egyptian Pharmaceutical Chemical Society (EPCS) 1999 – 2010. |
| **13** | **PARTICIPATION IN CONTINUING EDUCATION** | * Presenter, The Inauguration Symposium of The Computational Bio-Science Research Centre CBRC, King Abdullah City for Science and Technology, 2017, Thuwal, Saudi Arabia. * Presenter, 10th International Conference on Carbonic Anhydrase, 2016, Maastricht, Romania. * Presenter, The 2nd CA satellite meeting on Carbonic Anhydrases, 2013, Naples, Italy. * Presenter, International Conference on Phytochemicals in Health and Disease: Challenges and Future Opportunities (ICPHD), 2013, Madras, India. * Participant, The "9th International Conference on Carbonic Anhydrase, 2012, Antalya, Turkey. * Participant, New Horizons in Cancer Research: Biology to Prevention to Therapy, 2011, Delhi India. * Participant, The 4th International Conference for Development and the Environment, 2010, Riyadh, Saudi Arabia. * Participant, The 9th International Saudi Pharmaceutical Conference, 2009, Riyadh, Saudi. * Participant, The 7th International Pharmaceutical Sciences Conference and Exposition, 2008, Riyadh, * Participant, The 9th General Assembly Meeting of the Scientific Society of Colleges of Pharmacy of the Association of Arab Universities in the Arab World, 2007, Riyadh, Saudi Arabia. |
| **14** | **COMMUNITY SERVICES** | • Volunteer, Blood Donation Campaign, every now and then.  • Member, ICU, Egypt, 1985-present.  • Volunteer, help register people to vote in many elections.  • Organize a car wash and donate the profits to charity.  • Organize activities for children in hospitals and those visiting hospitalized relatives |